Who are Adlyxin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Albugon, Byetta, Byetta, Liraglutid, Bydureon, Rybelsus.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lixisenatide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Adlyxin — Competitive Intelligence Brief

Adlyxin (LIXISENATIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin Analog [EPC]. Area: Metabolic.

marketed Insulin Analog [EPC] Glucagon-like peptide 1 receptor Metabolic Recombinant protein Live · refreshed every 30 min

Target snapshot

Adlyxin (LIXISENATIDE) — Sanofi-Aventis Us Llc. Adlyxin works by mimicking the action of the GLP-1 hormone to help regulate blood sugar levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Adlyxin TARGET	LIXISENATIDE	Sanofi-Aventis Us Llc	marketed	Insulin Analog [EPC]	Glucagon-like peptide 1 receptor	2016-01-01
Albugon	ALBIGLUTIDE	GSK	marketed	GLP-1 Receptor Agonist	Glucagon-like peptide 1 receptor	2014-01-01
Byetta	EXENATIDE	AstraZeneca	marketed	GLP-1 Receptor Agonist [EPC]	Glucagon-like peptide 1 receptor	2005-01-01
Byetta	Byetta	AstraZeneca	marketed	GLP-1 Receptor Agonist [EPC]	Glucagon-like peptide 1 receptor	2005-01-01
Liraglutid	Liraglutid	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	marketed		Glucagon-like peptide 1 receptor
Bydureon	Bydureon	Phoenix VA Health Care System	marketed		Glucagon-like peptide 1 receptor, Glucagon-like peptide 1 receptor
Rybelsus	Rybelsus	Pfizer	marketed		Glucagon-like peptide 1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-08-18 — Byetta · 9884092 · US
2026-08-18 — Byetta · 8906851 · US
2026-08-18 — Byetta · 8329648 · US
2027-02-18 — Byetta · 9884092*PED · US
2027-02-18 — Byetta · 8906851*PED · US
2027-02-18 — Byetta · 8329648*PED · US
2027-06-20 — Byetta · 8501698 · US
2027-11-12 — Byetta · 8758292 · US
2027-12-20 — Byetta · 8501698*PED · US
2028-01-12 — Byetta · 8216180 · US
2028-03-21 — Byetta · 8361972 · US
2028-03-25 — Byetta · 9320853 · US
2028-03-25 — Byetta · 8439864 · US
2028-05-12 — Byetta · 8758292*PED · US
2028-07-12 — Byetta · 8216180*PED · US
2028-09-21 — Byetta · 8361972*PED · US
2028-09-25 — Byetta · 9320853*PED · US
2028-09-25 — Byetta · 8439864*PED · US
2029-02-04 — Byetta · 8827963 · US
2029-05-19 — Byetta · 8690837 · US
2029-08-04 — Byetta · 8827963*PED · US
2029-11-19 — Byetta · 8690837*PED · US
2030-01-07 — Byetta · 8998876 · US
2030-01-18 — Byetta · 8721615 · US
2030-07-07 — Byetta · 8998876*PED · US
2030-07-18 — Byetta · 8721615*PED · US
2030-10-04 — Byetta · 8895033 · US
2031-04-04 — Byetta · 8895033*PED · US

Sponsor landscape (Insulin Analog [EPC] class)

Novo Nordisk · 3 drugs in this class
Eli Lilly · 2 drugs in this class
Sanofi · 2 drugs in this class
Emory University · 1 drug in this class
Sanofi-Aventis Us Llc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adlyxin — Competitive Intelligence Brief. https://druglandscape.com/ci/lixisenatide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab